Scleroderma Withdrawn Phase Trials for Alemtuzumab (DB00087)

Also known as: Dermatosclerosis

IndicationStatusPhase
DBCOND0013449 (Scleroderma)WithdrawnNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01639573Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis